Latest Breaking News On - Anne brindley - Page 4 : comparemela.com

Nuformix eyes big opportunity with new forms of fibrosis and cancer drugs By developing new forms of safe drugs, the company generates its own intellectual property and may shorten the timeline to market You get the impression that Nuformix PLC (LON:NFX) chief executive Dr Anne Brindley is up for a good fight – in a business sense, that is. Her last role, with Australia’s Advent Pharmaceuticals, was a turnaround situation, which ended successfully with the sale of the business. “Who wants to go into a company and just maintain what’s been done before?” she asks. Her challenge at Nuformix is to find a licensing partner for the company’s lead asset, NXP002, a potential novel inhaled treatment for idiopathic pulmonary fibrosis (IPF).

United kingdomAnne brindleyRedx pharmaAustralia advent pharmaceuticalsAdvent pharmaceuticalsMorphic therapeuticsAllenby capitalஒன்றுபட்டது கிஂக்டம்அன்னே பிரிண்ட்லிமார்பிக் சிகிச்சைஆலன்பி மூலதனம்